Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX044 in advanced solid tumor malignancies
NCT06649708Phase 2Recruiting
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Fc Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of HX044 in solid tumor (advanced stage), sponsored by Hanx Biopharmaceuticals. Started Dec 2024; status: recruiting.
02
Drugs
HX044
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06649708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649708.